jain.com

FY2026 revenue guidance lowered

Company: Nebius

Subject kind
guidance
Statement date
2026-11-12
Promised by
2026-12-31
Promised amount
3000000000.0 USD
Current status
verified

The claim, verbatim

Nebius lowered its 2026 revenue guidance to $3.0B-$3.2B from the prior range of $3.0B-$3.4B.

Source (primary)

Prediction: Nebius Stock Will Trade At This Price at the End of 2027 - The Motley Fool (-, news_article)
View cached copy (2026-11-20)Live source ↗Archive.org ↗

Quote: “the company lowered its 2026 revenue guidance range to $3 billion-$3.2 billion from the prior range of $3 billion-$3.4 billion”

How we checked this

Checked on November 21, 2026. The cited source supports every part of this claim.

The article states that Nebius lowered its 2026 revenue guidance to $3 billion-$3.2 billion from a prior range of $3 billion-$3.4 billion.

Confirmed in the source:

What we did: Read our cached copy of the publisher (https://www.fool.com/investing/2026/11/19/prediction-nebius-stock-will-trade-at-this-price-at-the-end-of-2027/) in full (12,779 characters, retrieved November 20, 2026) and checked each assertion in the claim against it.

Additional evidence

confirms Prediction: Nebius Stock Will Trade At This Price at the End of 2027 - The Motley Fool

Quote: “the company lowered its 2026 revenue guidance range to $3 billion-$3.2 billion from the prior range of $3 billion-$3.4 billion”

View cached copy (2026-11-20)Live source ↗Archive.org ↗

confirms Nebius Stock Falls 10% After Q3 Earnings: Should You Buy Now? - Yahoo Finance

Quote: “For 2026, Nebius lowered its revenue guidance to $3-$3.2 billion from $3-$3.4 billion due to data center deployment delays”

View cached copy (2026-11-20)Live source ↗Archive.org ↗

Record of changes

November 20, 2026 — stated
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.
November 20, 2026 — verified
Automated extraction from the cited source. Recorded automatically from the cited source when it was published, then queued for evidence review.